This week, the overall grades of eight Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Merrimack Pharmaceuticals Inc.’s (NASDAQ:MACK) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Merrimack Pharmaceuticals is a biotechnology company, which is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. MACK also rates an F in Portfolio Grader’s specific subcategory of Cash Flow. The stock price has dropped 21% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. For a full analysis of MACK stock, visit Portfolio Grader.
Slipping from a C to a D rating, Genomic Health (NASDAQ:GHDX) takes a hit this week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also rates an F in Earnings Revisions. The stock currently has a trailing PE Ratio of 173.80. For more information, get Portfolio Grader’s complete analysis of GHDX stock.
Acorda Therapeutics (NASDAQ:ACOR) gets weaker ratings this week as last week’s C drops to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.
This is a rough week for Amarin (NASDAQ:AMRN). The company’s rating falls to D from the previous week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of July 17, 2013, 16.4% of outstanding Amarin shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
Exelixis (NASDAQ:EXEL) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of July 17, 2013, 19.5% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock.
This week, Trius Therapeutics’ (NASDAQ:TSRX) rating worsens to a D from the company’s C rating a week ago. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
Discovery Laboratories’ (NASDAQ:DSCO) rating weakens this week, dropping to a D versus last week’s C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. As of July 17, 2013, 10.2% of outstanding Discovery Laboratories shares were held short. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.
Achillion (NASDAQ:ACHN) is having a tough week. The company’s rating falls from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of July 17, 2013, 13.9% of outstanding Achillion shares were held short. For a full analysis of ACHN stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
